Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Easterly Investment Partners LLC

Easterly Investment Partners LLC lowered its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 10.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 65,232 shares of the medical equipment provider's stock after selling 7,349 shares during the period. Easterly Investment Partners LLC's holdings in Zimmer Biomet were worth $6,890,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Stonebridge Financial Group LLC purchased a new stake in Zimmer Biomet in the 4th quarter worth $25,000. Dunhill Financial LLC increased its holdings in shares of Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 218 shares during the last quarter. Brooklyn Investment Group purchased a new stake in shares of Zimmer Biomet during the 3rd quarter worth approximately $35,000. Kentucky Trust Co purchased a new position in shares of Zimmer Biomet in the fourth quarter valued at $39,000. Finally, OFI Invest Asset Management bought a new stake in Zimmer Biomet in the fourth quarter worth $40,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. JPMorgan Chase & Co. upgraded Zimmer Biomet from a "neutral" rating to an "overweight" rating and lifted their price target for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. Royal Bank of Canada dropped their target price on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, February 7th. Truist Financial restated a "hold" rating and set a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Raymond James dropped their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, Zimmer Biomet has a consensus rating of "Hold" and a consensus target price of $124.15.

Remove Ads

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This trade represents a 14.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.95% of the stock is currently owned by insiders.

Zimmer Biomet Stock Up 0.1 %

Shares of NYSE:ZBH traded up $0.06 on Friday, reaching $112.21. The company had a trading volume of 1,053,517 shares, compared to its average volume of 1,568,369. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $22.34 billion, a PE ratio of 25.22, a PEG ratio of 1.95 and a beta of 1.04. Zimmer Biomet Holdings, Inc. has a 52-week low of $97.69 and a 52-week high of $131.61. The firm's 50 day simple moving average is $107.18 and its 200-day simple moving average is $107.02.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the prior year, the company earned $2.20 EPS. As a group, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.86%. The ex-dividend date is Monday, March 31st. Zimmer Biomet's payout ratio is 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.